Posts

sstar-location

SSTAR Investigates Injectable Buprenorphine

SSTA- Investigates-Injectable-BuprenorphineIn addition to being a trusted addiction treatment services provider, Fall River-based Stanley Street Treatment and Resources Inc. ( SSTAR ) has been engaging in addiction research projects for many years, and is now helping to vet the next generation of medication-assisted treatment (MAT). SSTAR is currently investigating the safety and efficacy of injectable buprenorphine. This medication could potentially eliminate the need for daily visits to the clinic to receive doses. Patients who are eligible to participate in this pharmaceutical study will receive free buprenorphine treatment for up to 6 months and individualized weekly counseling. SSTARS Dr. Baily pointed out in a recent article that, “Access to cutting edge care through research is especially important to the uninsured and underinsured population by making access to treatment and medication easier and available at little to no cost to participants.”

Since 2002, Buprenorphine has been approved for the treatment of pain and opioid addiction in the form of tablets and film. According to the Substance Abuse and Mental Health Services Administration (SAMHSA) the properties of buprenorphine help to:

  • Lower the potential for misuse
  • Diminish the effects of physical dependency to opioids, such as withdrawal symptoms and cravings
  • Increase safety in cases of overdose

One manufacturer, Braeburn Pharmaceuticals and Camurus recently entered into the Phase 2 of their study of CAM2038, weekly and monthly subcutaneous buprenorphine injections. Behshad Sheldon, President and CEO, Braeburn Pharmaceuticals said, “Our goal is to provide a suite of best-in-class, long-acting treatment options tailored to the individual needs of patients suffering from opioid dependence and chronic pain.”

Read more in the article by Dr. Genie Bailey of SSTAR